Clinical Trials Logo

ESCC clinical trials

View clinical trials related to ESCC.

Filter by:
  • None
  • Page 1

NCT ID: NCT05547828 Not yet recruiting - ESCC Clinical Trials

Efficacy and Safety of Tislelizumab and Nab-paclitaxel Combined With Low-dose Radiotherapy in Patients With Stage IVb Esophageal Squamous Cell Carcinoma

Start date: December 20, 2022
Phase: Phase 2
Study type: Interventional

This study is a single-arm, prospective, open-label clinical study to evaluate the safety and efficacy of tislelizumab combined with chemoradiotherapy in first-line treatment of patients with stage IVb esophageal squamous cell carcinoma.

NCT ID: NCT05050760 Recruiting - ESCC Clinical Trials

DCF Combined With Camrelizumab in the Treatment of Esophageal Cancer

Start date: September 1, 2021
Phase: N/A
Study type: Interventional

To evaluate the safety and feasibility of DCF combined with camrelizumab in the treatment of locally advanced ESCC

NCT ID: NCT04939701 Completed - Ovarian Cancer Clinical Trials

Study of ASP0739 Alone and With Pembrolizumab in Advanced Solid Tumors With NY-ESO-1 Expression Participants

Start date: January 11, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety, and tolerability of ASP0739, when administered as a single agent and in combination with pembrolizumab. This study will also evaluate the clinical response and other measures of anticancer activity of ASP0739 when administered as a single agent and in combination with pembrolizumab based on central and local assessment.

NCT ID: NCT04863079 Recruiting - Pembrolizumab Clinical Trials

Pembrolizumab in Post Radical Operation ESCC Patients With Lymph Node Positive ( KEYSTONE-004 )

Start date: May 1, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study is to observe and evaluate the efficacy and safety of postoperative adjuvant treatment of pembrolizumab in patients with thoracic esophageal squamous cell carcinoma (ESCC) who have not received neoadjuvant therapy before undergoing R0 resection, and have positive postoperative lymph nodes.

NCT ID: NCT04686682 Recruiting - NSCLC Clinical Trials

A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors

Start date: May 7, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase 1/2a, first-in-human, open-label study of JAB-8263, this study has two parts: solid tumor dose escalation and expansion study and hematology tumor dose escalation and expansion study. These two parts will determine the maximum tolerated dose (MTD), recommended Phase 2 dose (RP2D) and assess the DLT of JAB-8263 in treatment with patients with advanced solid tumors and hematology tumors separately. 30 subjects each will be enrolled.

NCT ID: NCT04471480 Not yet recruiting - ESCC Clinical Trials

TC Plus PD-1 Inhibitors Combined With Anlotinib for Advanced Advanced Esophageal Cancer

TC
Start date: September 1, 2020
Phase: N/A
Study type: Interventional

A Controlled Clinical Study of TC/PD-1 Inhibitors Combined With anlotinib as First-line Treatment for Advanced ESCC